Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
O15169
UPID:
AXIN1_HUMAN
Alternative names:
Axis inhibition protein 1
Alternative UPACC:
O15169; Q4TT26; Q4TT27; Q86YA7; Q8WVW6; Q96S28
Background:
Axin-1, also known as Axis inhibition protein 1, plays a crucial role in the beta-catenin destruction complex, pivotal for Wnt-signaling modulation and cell development. It regulates CTNNB1 levels through phosphorylation and ubiquitination, influencing both cell growth and apoptosis. Axin-1's involvement in dorsoventral patterning and its function as a component of the AXIN1-HIPK2-TP53 complex underline its significance in cellular processes.
Therapeutic significance:
Axin-1's association with Hepatocellular carcinoma and Caudal duplication anomaly highlights its potential as a therapeutic target. Its role in disease pathogenesis, particularly through the hypermethylation of the AXIN1 promoter in Caudal duplication anomaly, underscores the importance of understanding Axin-1 in developing treatments for these conditions.